The combined benefits of a mineralocorticoid receptor antagonist (MRA), an angiotensin receptor-neprilysin inhibitor (ARNI), and a sodium-glucose cotransporter 2 (SGLT2) inhibitor in patients with ...

Dapagliflozin significantly reduced the risk of cardiovascular (CV) death or worsening of heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFpEF), according to ...

The clinical benefits of semaglutide (Wegovy; Novo Nordisk) in patients with the obesity phenotype of heart failure with preserved ejection fraction (HFpEF) don’t appear to be influenced by left ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Finerenone improved outcomes in patients with heart ...

Starting sacubitril/valsartan (Entresto) for recently decompensated heart failure with ejection fraction (EF) over 40% improved a key prognostic marker and, for those in the 40-60% range, clinical ...

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) Forxiga for expanded use to treat heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...